Summary of QQ1 2025 performance for Clearbridge Health Limited shows a revenue base of SGD 2.46 million with a gross margin near 48.4%, reflecting a robust product/service mix in imaging and clinic services. However, the quarter produced a net loss of SGD 0.677 million, with EBITDA of SGD -0.858 million and operating income of SGD -0.024 million, underscored by a sizable non-operating expense of SGD -0.778 million that weighed on pre-tax results. The company maintains a modest balance sheet risk profile (low leverage) and a workable liquidity position (current ratio 1.733; quick ratio 1.638), but operating cash flow remains negative and free cash flow per share is also negative, signaling ongoing cash burn in the near term.
Looking ahead, investors should focus on the trajectory of operating leverage, potential normalization or reduction of non-operating charges, and the company’s ability to convert revenue growth into improving margins. The absence of formal forward guidance in the presented data requires a cautious stance, with attention on cost controls, capex efficiency, and any strategic initiatives to expand imaging, diagnostics, and clinic-based services across the Singapore/Hong Kong/Malaysia/Philippines footprint. The stock trades with modest valuation multiples (P/S ~2.67, P/B ~0.54) despite a negative earnings signal, suggesting that upside may hinge on a clearer path to profitability and scalable revenue growth.